| 摘要: |
| 原发性免疫性血小板减少症(ITP)是一种免疫介导的出血性疾病,其特征是血小板计数减少和出血风险增加。传统的ITP治疗策略可通过减轻免疫介导的血小板破坏发挥治疗作用,如糖皮质激素、免疫球蛋白、免疫调节剂或脾切除术等。但许多患者对这些疗法响应性差,且与治疗相关的副作用和禁忌症也限制了其使用。近年来,促血小板生成素受体激动剂(TPO-RA),成为ITP 治疗新的选择。本文着重讨论TPO-RA的研发进展及安全性特征,旨在为TPO-RA的研发和临床用药提供参考。 |
| 关键词: 免疫性血小板减少症 血小板生成素受体激动剂 安全性特征 研发进展 |
| DOI:10.13506/j.cnki.jpr.2024.02.014 |
| 基金项目: |
|
|
|
| Progress and safety characteristics in thrombopoietin receptor agonists against immune thrombocytopenia |
| LIU Mingxia1,HAN Fengsheng2,LIU Yanzhen2,SUN Yunbei2 |
| (1. Shandong University, Jinan 250012,China;2.Shandong Luoxin Pharmaceutical Group Co., Ltd.,Linyi 276017,China) |
| Abstract: |
| Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Traditional ITP treatment strategies work through mitigating immune-mediated platelet destruction,such as glucocorticosteroids, immunoglobulins, immunomodulatory agents, or splenectomy. Although these strategies are usually effective, many patients have poor responsiveness to these therapies and their use is limited by treatment-related side effects and contraindications.In recent years, thrombopoietin receptor agonists (TPO-RA) ,by promoting platelet production,has become a new choice for the treatment of ITP. This article focuses on the progress and safety characteristics of TPO-RA, aiming to provide reference for the research and clinical use of TPO-RA. |
| Key words: Primary immune thrombocytopenia Thrombopoietin receptor agonists Safety characteristics Research and development progress |